[{"address1": "2929 7th Street", "address2": "Suite 105", "city": "Berkeley", "state": "CA", "zip": "94710", "country": "United States", "phone": "510 982 6030", "website": "https://cariboubio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.", "fullTimeEmployees": 158, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rachel E. Haurwitz Ph.D.", "age": 37, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1986, "fiscalYear": 2023, "totalPay": 979083, "exercisedValue": 0, "unexercisedValue": 486940}, {"maxAge": 1, "name": "Dr. Steven B. Kanner Ph.D.", "age": 63, "title": "Chief Scientific Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 669310, "exercisedValue": 0, "unexercisedValue": 447452}, {"maxAge": 1, "name": "Ms. Barbara G. McClung Esq., J.D.", "age": 68, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 669310, "exercisedValue": 0, "unexercisedValue": 402144}, {"maxAge": 1, "name": "Mr. Ryan  Fischesser", "title": "Interim Principal Accounting Officer, Interim Principal Financial Officer & Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Poon", "title": "Vice President of Operations & Information Technology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy P. Kelly M.B.A.", "age": 54, "title": "Chief Technology Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Figueroa C.F.A.", "title": "Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Reigin  Zawadzki", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruhi A. Khan M.B.A.", "age": 48, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 573900, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.78, "open": 2.82, "dayLow": 2.63, "dayHigh": 2.95, "regularMarketPreviousClose": 2.78, "regularMarketOpen": 2.82, "regularMarketDayLow": 2.63, "regularMarketDayHigh": 2.95, "beta": 2.263, "forwardPE": -1.3467337, "volume": 2463657, "regularMarketVolume": 2463657, "averageVolume": 1081907, "averageVolume10days": 2306700, "averageDailyVolume10Day": 2306700, "bid": 2.63, "ask": 2.72, "bidSize": 200, "askSize": 200, "marketCap": 242681248, "fiftyTwoWeekLow": 1.5, "fiftyTwoWeekHigh": 8.33, "priceToSalesTrailing12Months": 21.148693, "fiftyDayAverage": 2.0069, "twoHundredDayAverage": 3.381275, "currency": "USD", "enterpriseValue": 41144200, "floatShares": 81578916, "sharesOutstanding": 90552704, "sharesShort": 11510503, "sharesShortPriorMonth": 11628982, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.1274, "heldPercentInsiders": 0.10009, "heldPercentInstitutions": 0.62213004, "shortRatio": 14.05, "shortPercentOfFloat": 0.13350001, "impliedSharesOutstanding": 90362800, "bookValue": 3.105, "priceToBook": 0.863124, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -148120000, "trailingEps": -1.66, "forwardEps": -1.99, "pegRatio": -0.11, "enterpriseToRevenue": 3.586, "enterpriseToEbitda": -0.254, "52WeekChange": -0.292876, "SandP52WeekChange": 0.35905516, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CRBU", "underlyingSymbol": "CRBU", "shortName": "Caribou Biosciences, Inc.", "longName": "Caribou Biosciences, Inc.", "firstTradeDateEpochUtc": 1627047000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f11f6be1-a9a3-3c9c-bdb1-a1f42c197bdb", "messageBoardId": "finmb_272189231", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.68, "targetHighPrice": 30.0, "targetLowPrice": 3.0, "targetMeanPrice": 15.5, "targetMedianPrice": 13.5, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 228178000, "totalCashPerShare": 2.52, "ebitda": -161700000, "totalDebt": 26641000, "quickRatio": 7.178, "currentRatio": 7.383, "totalRevenue": 11475000, "debtToEquity": 9.474, "revenuePerShare": 0.128, "returnOnAssets": -0.2575, "returnOnEquity": -0.43598998, "freeCashflow": -81164376, "operatingCashflow": -124109000, "revenueGrowth": -0.914, "operatingMargins": -18.59585, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-11"}]